Probing the top-quark width through ratios of resonance contributions of e+e−→W+W−bbˉe^+e^-\rightarrow W^+W^-b\bar{b}

We exploit offshell regions in the process $e^+e^-\rightarrow W^+W^-b\bar{b}$ to gain access to the top-quark width. Working at next-to-leading order in QCD we show that carefully selected ratios of offshell regions to onshell regions in the reconstructed top and antitop invariant mass spectra are, \emph{independently} of the coupling $g_{tbW}$, sensitive to the top-quark width. We explore this approach for different centre of mass energies and initial-state beam polarisations at $e^+e^-$ colliders and briefly comment on the applicability of this method for a measurement of the top-quark width at the LHC.Comment: 31 pages, 10 figures, 2 table

Confrontation as a Coping Strategy to Protect Women\u27s Mental and Physical Health

Women suffer harmful consequences for mental and physical health after being exposed to sexism. In this study, I explored confrontation as a coping mechanism to protect women’s mental and physical health following an experience of sexism. This study consisted of a mock job search review in which the participant was exposed to blatant sexism and was instructed to confront or ignore the sexism. The participants completed measures of perceived sexism, psychological wellbeing, mental health, and physical health following the committee meeting. I hypothesized that women who were instructed to confront would do so and those instructed to ignore would not. I also expected that women in the confrontation condition would report higher psychological wellbeing, better mental health, and better physical health than those in the ignore condition. I found the manipulation of confrontation was effective, though I suggest some improvements for future research. My findings also pointed to initial support of confrontation as a protective mechanism for women’s psychological wellbeing, mental health, and physical health after experiencing sexism

Towards precise predictions for Higgs-boson production in the MSSM

We study the production of scalar and pseudoscalar Higgs bosons via gluon fusion and bottom-quark annihilation in the MSSM. Relying on the NNLO-QCD calculation implemented in the public code SusHi, we provide precise predictions for the Higgs-production cross section in six benchmark scenarios compatible with the LHC searches. We also provide a detailed discussion of the sources of theoretical uncertainty in our calculation. We examine the dependence of the cross section on the renormalization and factorization scales, on the precise definition of the Higgs-bottom coupling and on the choice of PDFs, as well as the uncertainties associated to our incomplete knowledge of the SUSY contributions through NNLO. In particular, a potentially large uncertainty originates from uncomputed higher-order QCD corrections to the bottom-quark contributions to gluon fusion.Comment: 62 pages, 24 pdf figures; v2: minor clarifications, improved plot quality, matches published versio

Money-Back Guarantees in Individual Retirement Accounts: Still a Good Deal?

Capital market volatility spurs interest in protecting retirement accounts; one such approach is to require money-back guarantees. Using a lifecycle model where investors have access to stocks, bonds, and tax-qualified retirement accounts, we show that such guarantees alter participant consumption, saving, and investment behavior during times of high interest rates, but impacts are even larger in a low-return environment. We conclude that abandoning guarantees could enhance old-age consumption for over 80% of retirees, particularly lower earners, without harming pre-retirement consumption. Our results are of interest for default investment options in individual retirement accounts such as the Pan-European Personal Pension Products

Interferon-γ Stimulates Monocyte Chemotactic Protein-1 Expression by Monocytes

Monocyte chemotactic protein (MCP-1) is a specific monocyte chemoattractant and activating factor produced by both immune cells (mononuclear phagocytes and lymphocytes) and non-immune cells (parenchymal and stromal cells). In order to define the conditions under which human monocytes express MCP-1, monocytes were exposed to IFN-γ, IL- lβ, TNF-α, IL-4 or PHA under serum free conditions. There was no significant MCP-1 production by monocytes following exposure to IL-lβ, TNF-α or IL-4. In contrast, stimulation with IFN-γ resulted in a dose dependent increase in MCP-1 protein and mRNA expression. Simultaneous stimulation with IFN-γ and IL-1β or TNF-α resulted in no further increase in MCP-1 production. It is concluded that IFN-γ, primarily a product of TH1 T lymphocytes, stimulates the expression of MCP-1 by monocytes

Vaccine-Induced Subcutaneous Granulomas in Goats Reflect Differences in Host–Mycobacterium Interactions between BCG- and Recombinant BCG-Derivative Vaccines

Tuberculous granulomas are highly dynamic structures reflecting the complex host–mycobacterium interactions. The objective of this study was to compare granuloma development at the site of vaccination with BCG and its recombinant derivatives in goats. To characterize the host response, epithelioid cells, multinucleated giant cells (MNGC), T cell subsets, B cells, plasma cells, dendritic cells and mycobacterial antigen were labelled by immunohistochemistry, and lipids and acid-fast bacteria (AFB) were labelled by specific staining. Granulomas with central caseous necrosis developed at the injection site of most goats though lesion size and extent of necrosis differed between vaccine strains. CD4(+) T and B cells were more scarce and CD8(+) cells were more numerous in granulomas induced by recombinant derivatives compared to their parental BCG strain. Further, the numbers of MNGCs and cells with lipid bodies were markedly lower in groups administered with recombinant BCG strains. Microscopic detection of AFB and mycobacterial antigen was rather frequent in the area of central necrosis, however, the isolation of bacteria in culture was rarely successful. In summary, BCG and its recombinant derivatives induced reproducibly subcutaneous caseous granulomas in goats that can be easily monitored and surgically removed for further studies. The granulomas reflected the genetic modifications of the recombinant BCG-derivatives and are therefore suitable models to compare reactions to different mycobacteria or TB vaccines

Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine. A post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial

Background: The PRESTO study of non-invasive vagus nerve stimulation (nVNS; gammaCore®) featured key primary and secondary end points recommended by the International Headache Society to provide Class I evidence that for patients with an episodic migraine, nVNS significantly increases the probability of having mild pain or being pain-free 2 h post stimulation. Here, we examined additional data from PRESTO to provide further insights into the practical utility of nVNS by evaluating its ability to consistently deliver clinically meaningful improvements in pain intensity while reducing the need for rescue medication. Methods: Patients recorded pain intensity for treated migraine attacks on a 4-point scale. Data were examined to compare nVNS and sham with regard to the percentage of patients who benefited by at least 1 point in pain intensity. We also assessed the percentage of attacks that required rescue medication and pain-free rates stratified by pain intensity at treatment initiation. Results: A significantly higher percentage of patients who used acute nVNS treatment (n = 120) vs sham (n = 123) reported a ≥ 1-point decrease in pain intensity at 30 min (nVNS, 32.2%; sham, 18.5%; P = 0.020), 60 min (nVNS, 38.8%; sham, 24.0%; P = 0.017), and 120 min (nVNS, 46.8%; sham, 26.2%; P = 0.002) after the first attack. Similar significant results were seen when assessing the benefit in all attacks. The proportion of patients who did not require rescue medication was significantly higher with nVNS than with sham for the first attack (nVNS, 59.3%; sham, 41.9%; P = 0.013) and all attacks (nVNS, 52.3%; sham, 37.3%; P = 0.008). When initial pain intensity was mild, the percentage of patients with no pain after treatment was significantly higher with nVNS than with sham at 60 min (all attacks: nVNS, 37.0%; sham, 21.2%; P = 0.025) and 120 min (first attack: nVNS, 50.0%; sham, 25.0%; P = 0.018; all attacks: nVNS, 46.7%; sham, 30.1%; P = 0.037). Conclusions: This post hoc analysis demonstrated that acute nVNS treatment quickly and consistently reduced pain intensity while decreasing rescue medication use. These clinical benefits provide guidance in the optimal use of nVNS in everyday practice, which can potentially reduce use of acute pharmacologic medications and their associated adverse events. Trial registration: ClinicalTrials.gov identifier: NCT02686034